- Report
- March 2026
- 280 Pages
United States
From €4403EUR$4,850USD£3,793GBP
- Report
- March 2026
- 178 Pages
China
From €4403EUR$4,850USD£3,793GBP
- Report
- March 2026
- 212 Pages
Germany
From €4403EUR$4,850USD£3,793GBP
- Report
- March 2026
- 150 Pages
Canada
From €4403EUR$4,850USD£3,793GBP
- Report
- March 2026
- 246 Pages
India
From €4403EUR$4,850USD£3,793GBP
- Report
- December 2024
- 150 Pages
Global
From €4403EUR$4,850USD£3,793GBP
Cefteram is a class of antibiotics used to treat a variety of bacterial infections. It is a cephalosporin antibiotic, which works by inhibiting the growth of bacteria. Cefteram is used to treat a wide range of infections, including respiratory tract infections, urinary tract infections, skin and soft tissue infections, and bone and joint infections. Cefteram is also used to prevent infections in people undergoing certain medical procedures.
The Cefteram market is composed of pharmaceutical companies that manufacture and market Cefteram-based products. These products are available in various forms, such as tablets, capsules, and injections. Cefteram is also available in combination with other antibiotics, such as clavulanic acid, to increase its effectiveness.
Some of the companies in the Cefteram market include Pfizer, Merck, GlaxoSmithKline, Sanofi, and AstraZeneca. Show Less Read more